PepGen DSMB backs advance of PGN-EDODM1 to top dose in FREEDOM2-DM1
The safety board also cleared a dose escalation in the open-label extension study, as PepGen posted second-quarter 2026 results showing $117.2 million in cash.
SEC filing
Latest
1 story